AG
CLDX icon

Aperio Group’s Celldex Therapeutics CLDX Stock Holding History

Aperio Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8
Closed – – 2398
2019
Q2 		$0 Buy
+8
New +$27 ﹤0.01% 3027
2016
Q4 		– Sell
-786
Closed -$48K – 2120
2016
Q3 		$48K Buy
+786
New +$48.9K ﹤0.01% 2043
2016
Q1 		– Sell
-1,644
Closed -$387K – 2034
2015
Q4 		$387K Buy
1,644
+85
+5% +$18.5K ﹤0.01% 1468
2015
Q3 		$246K Sell
1,559
-285
-15% -$80.7K ﹤0.01% 1659
2015
Q2 		$698K Buy
1,844
+312
+20% +$124K 0.01% 1142
2015
Q1 		$640K Sell
1,532
-16
-1% -$5.72K 0.01% 1142
2014
Q4 		$424K Buy
1,548
+24
+2% +$5.97K 0.01% 1321
2014
Q3 		$296K Buy
+1,524
New +$332K ﹤0.01% 1402

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aperio Group's CLDX Position: Q3 2019 in Review

Aperio Group sold out of Celldex Therapeutics (CLDX) in Q3 2019, closing a stake of 8 shares.

Aperio Group first reported a position in CLDX in Q3 2014 and held it in 8 quarters. The position peaked at $698K in Q2 2015. 54 funds tracked by Wall St. Rank hold CLDX as of Q3 2019.

  • Aperio Group reported no remaining Celldex Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 8 Celldex Therapeutics shares in Q3 2019.
  • Aperio Group first reported a position in Celldex Therapeutics in Q3 2014 and held it in 8 quarters.
  • Aperio Group's Celldex Therapeutics position peaked at $698K in Q2 2015.
  • 54 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.